Valbiotis obtains patent for its active substance TOTUM-63 in China.

China, whose economic development has been accompanied by an explosion of metabolic disorders since the 2000s, is now believed to have the largest prediabetic population in the world, with an estimated 390 million people (35% of the adult population).

Valbiotis is achieving its global protection strategy, with the TOTUM-63 patent now acquired in nearly 50 countries including Europe, the United States and China, to market this active substance worldwide in partnership with Nestlé Health Science.